Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4791165 | 0.88 | MAPKAPK2 (0.46) | MAPKAPK2MAPTTDP1POLBALDH1A1 | |
| SCHEMBL4717070 | 0.87 | MAPKAPK2 (0.47) | MAPKAPK2MAPTABL1BCRGCGR | |
| Trifluoroacetic Acid SCHEMBL4718393 | 0.87 | MAPKAPK2 (0.47) | MAPKAPK2MAPTSMN1; SMN2TDP1POLB | |
| Trifluoroacetic Acid SCHEMBL4714469 | 0.86 | MAPKAPK2 (0.58) | MAPKAPK2MAPTFLT3ABL1BCR | |
| SCHEMBL14188347 | 0.85 | MAPKAPK2 (0.50) | MAPKAPK2MAPTSMN1; SMN2TDP1POLB | |
| SCHEMBL14188284 | 0.84 | MAPKAPK2 (0.64) | MAPKAPK2MAPTFLT3ABL1BCR | |
| SCHEMBL4714052 | 0.83 | MAPKAPK2 (0.47) | MAPKAPK2MAPTSMN1; SMN2ALDH1A1FYN | |
| SCHEMBL4718583 | 0.83 | MAPKAPK2 (0.40) | MAPKAPK2MAPTSMN1; SMN2TDP1POLB | |
| SCHEMBL4713527 | 0.82 | MAPKAPK2 (0.73) | MAPKAPK2HDAC1 | |
| SCHEMBL4716306 | 0.78 | MAPKAPK2 (0.57) | MAPKAPK2MAPTABL1BCRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| EP-1572682-A4 | ACYCLIC PYRAZOLE COMPOUNDS | PHARMACIA CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1572682-A2 | ACYCLIC PYRAZOLE COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040152739-A1 | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-08-05 | — | — | US | disclosed |
| WO-2004058176-A2 | ACYCLIC PYRAZOLE COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | MAPKAPK2 2/4885MAPT 1363/4885FLT3 975/4885 |
| US-20040152739-A1 | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MAPKAPK2, MAP3K2, MAP4K2 | MAPKAPK2 1/4885MAPT 2038/4885FLT3 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.